If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
About Cancer BiomarkersBiomarkers are molecules present in the blood, other body fluids such as serum, urine, or in tissue that are indicators of a disease or abnormal conditions. Biomarkers are mostly used as diagnostic tools. Biomarkers help in identifying potential drug failures in initial stages, leading to savings in time and costs. Biomarkers are becoming an essential part of the drug discovery process. Cancer Biomarkers are proteins or metabolites indicative of tumor state and progression characteristics. They are non-invasive, enable high speed cancer diagnosis and also enhance early cancer detection and screening. The best example of a cancer biomarker is that of prostate specific antigen. PSA is measured in the blood to screen for and monitor treatment for prostate cancer. PSA, as a biomarker helps the doctors to monitor the progress of the cancer. It also helps to evaluate the response of the cancer to the treatment therapy.TechNavio's analysts forecast the Global Cancer Biomarkers market to grow at a CAGR of 18.26 percent over the period 2014-2019.Covered in this ReportGlobal Cancer Biomarkers Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cancer Biomarkers market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions Americas APAC EMEAKey Vendors Abbott Laboratories Affymetrix Illumina Qiagen Quest Diagnostics Roche DiagnosticsOther Prominent Vendors Agendia Agilent Technologies Alere Ambry Genetics Amgen Astellas Pharma US Astex Pharmaceuticals Atossa Genetics Beckman Coulter Becton, Dickinson and Company Biocurex bioMιrieux Celldex Therapeutics Clarient diaDexus DiagnoCure Epigenomics EUSA Pharma Exact Sciences Foundation Medicine Fujirebio Diagnostics Genomic Health Geron Immunomedics Morphotek Myriad Genetics Nodality Northwest Biotherapeutics Ocimum Biosolutions Oncothyreon OriGene Polymedco Radient Pharmaceuticals Randox Laboratories Siemens Healthcare US Biomarkers VermillionMarket Driver Increased Prevalence of Cancer For a full, detailed list, view our reportMarket Challenge Regulatory and Reimbursement Issues For a full, detailed list, view our reportMarket Trend Growing Popularity of Companion Diagnostics For a full, detailed list, view our reportKey Questions Answered in this Report What will the market size be in 2019 and what will the growth rate be? What are the key market trends? What is driving this market? What are the challenges to market growth? Who are the key vendors in this market space? What are the market opportunities and threats faced by the key vendors? What are the strengths and weaknesses of the key vendors?
Table of Contents01. Executive Summary02. List of Abbreviations03. Scope of the Report03.1 Market Overview03.2 Product Offerings04. Market Research Methodology04.1 Market Research Process04.2 Research Methodology05. Introduction06. Market Landscape06.1 Market Overview06.2 Market Size and Forecast06.3 Five Forces Analysis07. Incidence and Prevalence08. Biomarkers Used in Cancer Diagnosis08.1.1 Cancer Biomarkers : FDA Approved till 201208.1.2 Cancer Biomarkers : FDA Approved 201309. FDA Approval Process for Protein-Based Cancer Biomarkers10. Geographical Segmentation10.1 Cancer Biomarkers Market in the Americas10.1.1 Market Size and Forecast10.1.2 Cancer Biomarkers Market in US10.2 Cancer Biomarkers Market in the EMEA Region10.2.1 Market Size and Forecast10.3 Cancer Biomarkers Market in APAC Region10.3.1 Market Size and Forecast11. Buying Criteria12. Market Growth Drivers13. Drivers and their Impact14. Market Challenges15. Impact of Drivers and Challenges16. Market Trends17. Trends and their Impact18. Vendor Landscape18.1 Competitive Scenario18.1.1 Key News18.1.2 Mergers and Acquisitions18.2 Vendor Analysis 201418.3 Other Prominent Vendors19. Key Vendor Analysis19.1 Abbott Laboratories19.1.1 Key Facts19.1.2 Business Description19.1.3 Business Segmentation19.1.4 Business Strategy19.1.5 Revenue by Business Segmentation19.1.6 Revenue Comparison 2011 and 201219.1.7 Revenue by Geographical Segmentation19.1.8 Key Information19.1.9 SWOT Analysis19.2 Affymetrix19.2.1 Key Facts19.2.2 Business Overview19.2.3 Business Segmentation19.2.4 Business Segmentation by Revenue 201319.2.5 Business Segmentation by Revenue 2012 and 201319.2.6 Sales by Geography19.2.7 Business Strategy19.2.8 Key Information19.2.9 SWOT Analysis19.3 Illumina19.3.1 Key Facts19.3.2 Business Overview19.3.3 Business Segmentation19.3.4 Geographical Segmentation by Revenue 201319.3.5 Business Strategy19.3.6 Key Information19.3.7 SWOT Analysis19.4 Qiagen19.4.1 Key Facts19.4.2 Business Overview19.4.3 Product Segmentation by Revenue 201319.4.4 Product Segmentation by Revenue 2012 and 201319.4.5 Geographical Segmentation by Revenue 201319.4.6 Business Strategy19.4.7 Recent Developments19.4.8 SWOT Analysis19.5 Quest Diagnostics19.5.1 Key Facts19.5.2 Business Overview19.5.3 Business Segmentation by Revenue 201319.5.4 Business Segmentation by Revenue 2011-201319.5.5 Geographical Segmentation by Revenue 201319.5.6 Business Strategy19.5.7 Recent Developments19.5.8 SWOT Analysis19.6 Roche Diagnostics19.6.1 Key Facts19.6.2 Business Overview19.6.3 Business Segmentation by Revenue 201319.6.4 Geographical Segmentation by Revenue 201319.6.5 Business Strategy19.6.6 Key Developments19.6.7 SWOT Analysis20. Other Reports in this SeriesList of ExhibitsExhibit 1: Market Research MethodologyExhibit 2: Global Cancer Biomarkers Market 20142019 (US$ billion)Exhibit 3: Incidence of Various Types of Cancer in 2012Exhibit 4: FDA Classification of Medical Devices by Type of ClassExhibit 5: Global Cancer Biomarkers Market by Geographical Segmentation 2014Exhibit 6: Global Cancer Biomarkers Market by Geographical Segmentation 2019Exhibit 7: Cancer Biomarkers Market in the Americas 2014-2019 (US$ billion)Exhibit 8: Cancer Biomarkers Market in US 2014-2019 (US$ billion)Exhibit 9: Cancer Biomarkers Market in the EMEA Region 2014-2019 (US$ billion)Exhibit 10: Cancer Biomarkers Market in the APAC Region 2014-2019 (US$ billion)Exhibit 11: Global Cancer Biomarkers Market by Geographical Segmentation 2014-2019Exhibit 12: Abbott Laboratories Inc.: Business SegmentationExhibit 13: Abbott Laboratories Inc.: Revenue by Business Segmentation 2012Exhibit 14: Abbott Laboratories Inc.: Revenue by Business Segmentation 2011 and 2012 (US$ million)Exhibit 15: Abbott Laboratories Inc.: Revenue by Geographical Segmentation 2012Exhibit 16: Affymetrix Inc.: Business Segmentation 2013Exhibit 17: Affymetrix Inc.: Business Segmentation by Revenue 2013Exhibit 18: Affymetrix Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ million)Exhibit 19: Affymetrix Inc.: Sales by Geography 2013Exhibit 20: Illumina: Business SegmentationExhibit 21: Illumina: Geographical Segmentation by Revenue 2013Exhibit 22: Qiagen: Product Segmentation by Revenue 2013Exhibit 23: Qiagen: Product Segmentation by Revenue 2012 and 2013 (US$ million)Exhibit 24: Qiagen: Geographical Segmentation by Revenue 2013Exhibit 25: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2013Exhibit 26: Global Cancer Biomarkers Market: Business Segmentation by Revenue 2011-2013 (US$ billion)Exhibit 27: Global Cancer Biomarkers Market: Geographical Segmentation by Revenue 2013Exhibit 28: Roche Diagnostics: Business Segmentation by Revenue 2013Exhibit 29: Roche Diagnostics: Geographical Segmentation by Revenue 2013